Ritonavir and saquinavir combination therapy for the treatment of HIV infection

AIDS

Volumn 13, Issue 2, 1999, Pages 213-224

  Cameron, D William ^a   Japour, Anthony J ^b   Xu, Yi ^b   Hsu, Ann ^b   Mellors, John ^c   Farthing, Charles ^d   Cohen, Calvin ^e   Poretz, Donald ^f   Markowitz, Martin ^g   Follansbee, Steve ^h,j   Angel, Jonathan B ^a   McMahon, Deborah ^c   Ho, David ^g   Devanarayan, Viswanath ^b   Rode, Richard ^b   Salgo, Miklos P ⁱ   Kempf, Dale J ^b   Granneman, Richard ^b   Leonard, John M ^b   Sun, Eugene ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d AIDS HEALTHCARE FOUNDATION   (United States)

^e Comm Res Initiative of New England ^*  (United States)

^f Infectious Diseases Physicians Inc   (United States)

^g AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^h Inst for HIV Research and Treatment   (United States)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j Kaiser Medical Center   (United States)

more..

Author keywords

Antiretroviral therapy; Combination therapy

Indexed keywords

AMINOTRANSFERASE; CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; UNITED STATES; VERTIGO; VOMITING;

ADULT; ANTI-HIV AGENTS; CONSUMER PRODUCT SAFETY; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 0032971472     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00009     Document Type: Article

References (29)

1. Hammer S, Squires K, Hughes M, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and Iamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Cameron D, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
4. Deeks S, Smith M, Holodniy M, Kahn J: HIV-1 protease inhibitors. JAMA 1997, 277:145-153.
5. Kempf D, Rode R, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
6. Kohl NE, Emini EA, Schleif WA, et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl Acad Sci USA 1988, 85:4686-4690.
7. Peng C, Ho BK, Chang TW, Chang NI: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989, 63:2550-2556.
8. Seelmeier S, Schmidt H, Turk V, von der Helm K: Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA 1988, 85:6612-6616.
9. Roberts NA, Martin JA, Kinchington D, et al.: Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248:358-361.
10. Kempf D, Marsh KC, Denissen J, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92:2484-2488.
11. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl Med 1996, 334:1011-1017.
12. Lalezari J, Haubrich R, Burger H, et al.: Improved survival and decreased progression of HIV in patients treated with saquinavir plus zalcitabine. XI International Conference on AIDS. Vancouver, British Columbia 1996. I.B.B.6033.
13. Shapiro J, Winters M, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Int Med 1996, 124:1039-1050.
14. IM package insert. Roche Laboratories, Inc., 1998.
15. Kempf D, Marsh K, Kumar G, et al.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660.
16. Hsu A, Granneman G, Cao G, et al.: Pharmacokinetic interactions between two HIV-protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63(4):453-464.
17. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
18. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996, 2:760-766.
19. Jacobsen H, Haenggi M, Ott M, Duncan I, Vella S, Mous J: In vivo resistance to HIV protease inhibitor saquinavir - an update. AIDS Res Hum Retroviruses 1995, 11:S169.
20. Division of AIDS: Division of AIDS table for grading severity of adult adverse experiences 1996. National Institute of Allergy and Infectious Diseases, Rockville, MD.
21. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield I, Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994, 32:292-300.
22. Marsh KC, Eiden E, McDonald E: Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr 1997, 704:307-313.
23. Molla A, Granneman G, Sun E, Kempf D: Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998, 39(1):1-23.
24. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Croup Study 175 Study Team. N Engl J Med 1996, 335:1081-1090.
25. Race E, Adelson-Mitty I, Kriegel G, et al.: Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351:252-255.
26. Carr A, Cooper D: Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:996-997.
27. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D. Perrin I: Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C in patients coinfected with HIV. J Infect Dis. 1998, 177:783-785.
28. Invirase™ package insert. Roche Laboratories, Inc., 1998.
29. Buss N, on behalf of the Fortovase Study Group: Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998: Abstract 354, p.145.